Dermatology Times: Alphyn Biologics Shares Positive Interim Results of Phase 2a Trial for AD With Secondary Bacterial Infection
Kaitlyn Bader, Senior Editor
![Alphyn Logo 1 Alphyn Logo 1](https://v769c6.p3cdn1.secureserver.net/wp-content/uploads/2021/04/Alphyn-Logo-1-200x200.png)
AB-101a is a new topical treatment being investigated for mild, moderate, and severe atopic dermatitis and its immune system component.
CONTACTS
Corporate:
Neal Koller
nkoller@alphynbiologics.com
(410) 690-8687
Media:
Susan Thomas
susan@endpointcommunications.net
(619) 540-9195